RELIANCE BIOSCIENCES delivers frontier molecular diagnostics for early Alzheimer’s disease (AD) via protein markers from exosomes in blood.

Exosomes are nanoparticles secreted from disease-specific cells and provide personalized and actionable disease insights. Our proprietary immunoassay technology enables high sensitivity exosomal protein detection using blood.

We are a startup from the National Taiwan University with 15 years of experience working with physicians. We have successfully executed an extremely competitive grant of USD 1.1M. Our medical team includes physicians from the National Taiwan University Hospital, Harvard Medical School and Massachusetts General Hospital.

OUR CURRENT FOCUS

Early detection of Alzheimer’s since it can be detected up to 15-20 years before the disease onset

OUR CURRENT FOCUS

Early detection of Alzheimer’s since it can be detected up to 15-20 years before the disease onset

Unmet need

1
million

Americans living with Alzheimer’s  in 2019

1
million

Americans estimated to have Alzheimer’s by 2050

1
million

People living with Alzheimer’s worldwide in 2019

in our PIPELINE

Our high-sensitivity immune-platform has the build-in flexibility to detect other disease indications. Our strong pipeline includes solid tumors in colorectol, lung, and gastric cancers. Each indication has a tailor go-to-market strategy after much interaction from KOL physicians.

partner with us

We are seeking partnership with diagnostic labs in laboratory-developed test (LDT) of early Alzheimer’s disease in Japan and USA.

TECHNICAL MILESTONES

1. Seed grant

Seed grant of USD 1.1 million successfully executed.

2. Licensing

Exclusively licensed technology from the National Taiwan University.

3. Prototypes

RExo-system completed: (a) RExo-analyzer: multiplex sample preparation & analysis and (b) RExo-assay: multiplex fluidic assay

4. Executed Agreement

Fully executed agreement with an Australian Alzheimer organization with 8,500 contact-patient-year samples available for fast-track study on AD, with PET scan data as control.

5. MTA executed

MTA fully executed with Harvard Med School/MGH with 500 samples for early assessment of lung cancer.

6. NDA executed

Multiple NDAs fully executed with pharmas and organizations towards clinical development.